Compare Gilead Sciences, Inc. (GILD) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs The Coca-Cola Co K — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while The Coca-Cola Co K trades at $88.05 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 2.1× Gilead Sciences, Inc.'s market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and The Coca-Cola Co K for 154 Days on average.
| GILD | KO | |
|---|---|---|
Market Cap | $182.40B | $377.63B |
Volume | 4,469,821 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $91.99 |
52-Week Low | $116.74 | $66.37 |
Typical Hold Time | 111 Days | 154 Days |
Enterprise Value | $205.46B | $404.81B |
Dividend Yield | 2.23% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Coca-Cola (KO) trades at $87.77, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 28.56% net margin, and 44.23% ROE. Recent institutional buying activity and positive analyst sentiment (60% buy ratings) support the stock's upward trajectory. KO maintains its dividend aristocrat status with 64 consecutive years of dividend increases, paying $0.53 per share in the upcoming H2-26 distribution.
KO presents a compelling investment case with stable revenue growth, exceptional profitability, and strong institutional support. The stock trades at a premium valuation (P/E 26.36) but justifies it with consistent execution. Key risks include regional demand divergence in Asia and elevated debt levels. With a consensus price target of $95.75 offering 9% upside potential, KO remains a quality defensive holding for dividend-focused investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
